Drug Profile
Research programme: enzyme linked antibody nutrient depletion therapy - KS Biomedix Holdings
Alternative Names: ELANDT research programme - KS Biomedix Holdings; Enzyme linked antibody nutrition depletion therapy research programme - KS Biomedix Holdings; Research programme: ELANDT - KS Biomedix HoldingsLatest Information Update: 30 Sep 2002
Price :
$50
*
At a glance
- Originator KS Biomedix Holdings
- Class Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 28 Sep 2002 Discontinued - Preclinical for Colorectal cancer in United Kingdom (unspecified route)
- 22 May 2001 Preclinical development for Colorectal cancer in United Kingdom (Unknown route)